scholarly journals Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer

Cancer ◽  
2011 ◽  
Vol 117 (14) ◽  
pp. 3193-3200 ◽  
Author(s):  
Tom Donnem ◽  
Kenneth Lonvik ◽  
Katrine Eklo ◽  
Thomas Berg ◽  
Sveinung W. Sorbye ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Prognostic Impact ◽  
Tissue Specific

scholarly journals Predictive and prognostic impact of primary tumor‐bearing lobe in nonsmall cell lung cancer patients treated with anti‐PD ‐1 therapy

2020 ◽  
Vol 147 (8) ◽  
pp. 2327-2334 ◽  
Author(s):  
Shinkichi Takamori ◽  
Kazuki Takada ◽  
Mototsugu Shimokawa ◽  
Taichi Matsubara ◽  
Naoki Haratake ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Nonsmall Cell Lung Cancer ◽  
Prognostic Impact ◽  
Lung Cancer Patients ◽  
Tumor Bearing

scholarly journals Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer

Cancer ◽  
2011 ◽  
Vol 118 (9) ◽  
pp. 2454-2465 ◽  
Author(s):  
Jin-Soo Kim ◽  
Edward S. Kim ◽  
Diane Liu ◽  
J. Jack Lee ◽  
Luisa Solis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Insulin Receptor ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Receptor Expression ◽  
Prognostic Impact ◽  
Insulin Receptor Expression

scholarly journals Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA

2015 ◽  
Vol 24 (136) ◽  
pp. 340-355 ◽  
Author(s):  
Sandra Wallerek ◽  
Jens Benn Sørensen
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Cell Lung Cancer ◽  
Current Knowledge ◽  
Nonsmall Cell Lung Cancer ◽  
Chemotherapeutic Agents ◽  
Complete Resection ◽  
Prognostic Impact ◽  
Gene Profile ◽  
Nsclc Patients

Biomarkers may be useful when deciding which nonsmall cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy following complete resection and which chemotherapeutic agents may be used preferably in individual patients in order to maximise survival.A literature search covering the period from 2003 to May, 2014 was conducted using PubMed and the following search terms: “non-small cell lung cancer”, “NSCLC”, “adjuvant chemotherapy”, “randomized”, “randomised”, “biomarkers”, “prognostic”, “predictive”. This review focuses on current knowledge of biomarkers for prognosis or efficacy of adjuvant treatment following complete resection in stage I–IIIA NSCLC patients.This review includes results on 18 different biomarkers and five gene profiles. A statistically significant prognostic impact was reported for: iNTR, TUBB3, RRM1, ERCC1, BRCA1, p53, MRP2, MSH2, TS, mucin, BAG-1, pERK1/2, pAkt-1, microRNA, TopIIA, 15-gene profile, 92-gene profile, 31-gene profile and 14-gene profile. A statistically significant predictive impact was reported for: ERCC1, p53, MSH2, p27, TUBB3, PARP1, ATM, 37-gene profile, 31-gene profile, 15-gene profile and 92-gene profile.Uncertainties regarding the optimal analysis method and cut-off levels for the individual markers may blur the prognostic or predictive signals. None of the possible predictive markers have been validated in prospective trials. Thus, there are no biomarkers ready to use in an adjuvant setting in NSCLC.

scholarly journals Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer

Cancer ◽  
2010 ◽  
Vol 116 (24) ◽  
pp. 5676-5685 ◽  
Author(s):  
Tom Donnem ◽  
Sigve Andersen ◽  
Khalid Al-Shibli ◽  
Samer Al-Saad ◽  
Lill-Tove Busund ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Prognostic Impact ◽  
Notch Ligands

The Prognostic Impact of Pericardial Fat Volumes in Resected Non-small Cell Lung Cancer

2019 ◽  
Vol 27 (2) ◽  
pp. 481-489 ◽  
Author(s):  
Shuichi Shinohara ◽  
Ryo Otsuki ◽  
Kenichi Kobayashi ◽  
Masaki Matsuo ◽  
Ken Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Pericardial Fat

scholarly journals Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

2021 ◽  
Vol 9 (3) ◽  
pp. e002262
Author(s):  
Justin Ferdinandus ◽  
Martin Metzenmacher ◽  
Lukas Kessler ◽  
Lale Umutlu ◽  
Clemens Aigner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Standard Of Care ◽  
Nonsmall Cell Lung Cancer ◽  
Published Data ◽  
Complete Metabolic Response ◽  
Positron Emission ◽  
Checkpoint Inhibitor Therapy

IntroductionImmunotherapy is the new standard of care in advanced nonsmall cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy.MethodsThis is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. ResultsOut of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months.ConclusionAfter a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.

scholarly journals Aberrantp16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer

2003 ◽  
Vol 106 (6) ◽  
pp. 913-918 ◽  
Author(s):  
Sonata Jarmalaite ◽  
Annamaria Kannio ◽  
Sisko Anttila ◽  
Juozas R. Lazutka ◽  
Kirsti Husgafvel-Pursiainen
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Nonsmall Cell Lung Cancer ◽  
Former Smokers
Sign in / Sign up

Export Citation Format

Share Document